- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.03. | Silexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | 242 | GlobeNewswire (Europe) | Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting... ► Artikel lesen | |
| 24.03. | Silexion receives Israeli approval for pancreatic cancer trial | 1 | Investing.com | ||
| 23.03. | Silexion Therapeutics: Aktionäre lehnen Kapitalerhöhung und Ausweitung des Aktienplans ab | 2 | Investing.com Deutsch | ||
| 23.03. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Silexion Therapeutics reports Q4 results | 1 | Seeking Alpha | ||
| 17.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 330 | GlobeNewswire (Europe) | Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer... ► Artikel lesen | |
| 17.03. | Silexion Therapeutics Corp - 10-K, Annual Report | 4 | SEC Filings | ||
| 19.02. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.02. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Silexion Therapeutics Corp: Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit | 2 | GlobeNewswire (USA) | ||
| 06.01. | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | 334 | GlobeNewswire (Europe) | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen | |
| 06.01. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Silexion Therapeutics Corp: Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer | 426 | GlobeNewswire (Europe) | Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains... ► Artikel lesen | |
| 25.11.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Silexion Therapeutics GAAP EPS of -$2.88 | 2 | Seeking Alpha | ||
| 12.11.25 | Silexion Therapeutics Corp Announces Drop In Q3 Bottom Line | 3 | RTTNews |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,75 | +2,91 % | BioNTech-Aktie: Wann geht's wieder über 100 Euro? | BioNTech hat neue klinische Daten zu einem wichtigen Krebsmedikament veröffentlicht und damit erneut Fortschritte in seiner Onkologie-Pipeline demonstriert. Für Investoren sind solche Studiendaten entscheidend... ► Artikel lesen | |
| AMGEN | 297,35 | +0,78 % | $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today | ||
| NOVAVAX | 7,310 | -0,68 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 148,70 | -2,80 % | Piper Sandler upgrades Biogen stock rating on acquisition strength | ||
| VIKING THERAPEUTICS | 30,100 | +0,17 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,504 | -7,70 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 11,880 | -6,16 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 46,000 | -3,84 % | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,110 | +1,30 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2026 Financial Results on May 6 | ||
| BIOMARIN PHARMACEUTICAL | 46,820 | -1,04 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,800 | -3,37 % | Sarepta/Roche Duchenne therapy to face new late-stage trial targeting EU nod | ||
| EXELIXIS | 37,395 | -0,36 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,358 | -0,15 % | PacBio und Covaris entwickeln Workflow für die Sequenzierung von FFPE-Gewebeproben | ||
| CARDIOL THERAPEUTICS | 1,162 | -2,84 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart | Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,91 % bei einem Aktienkurs von 1,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.